Literature DB >> 25312325

[Procalcitonin as a marker of intra-abdominal infection].

Elías Domínguez-Comesaña1, Julio Roberto Ballinas-Miranda2.   

Abstract

BACKGROUND: Procalcitonin is a quite specific biomarker of infection and in recent years has shown its superiority to others markers of inflammation, such as C-reactive protein, for the diagnosis and monitoring of a variety of infections. AIM: For this reason, several researchers have studied the potential role of procalcitonin for diagnosis and management of these infections. DISCUSSION: Intra-abdominal infections are a heterogeneous group of infections that, sometimes, pose difficult challenges to physicians. The published studies have produced mixed results, leading to controversy on the utility of this marker in intra-abdominal infections.
CONCLUSIONS: This review summarizes these data and discuss the utility of procalcitonin in several intra abdominal infections, including postoperative infections.

Entities:  

Keywords:  Procalcitonin; apendicitis; bowel ischemia; infección postoperatoria; isquemia intestinal; pancreatitis; peritonitis; postoperative infection; procalcitonina

Mesh:

Substances:

Year:  2014        PMID: 25312325

Source DB:  PubMed          Journal:  Cir Cir        ISSN: 0009-7411            Impact factor:   0.361


  3 in total

Review 1.  Procalcitonin in inflammatory bowel disease: Drawbacks and opportunities.

Authors:  Giuseppe Lippi; Fabian Sanchis-Gomar
Journal:  World J Gastroenterol       Date:  2017-12-21       Impact factor: 5.742

2.  Procalcitionin as a diagnostic marker to distinguish upper and lower gastrointestinal perforation.

Authors:  Yang Gao; Kai-Jiang Yu; Kai Kang; Hai-Tao Liu; Xing Zhang; Rui Huang; Jing-Dong Qu; Si-Cong Wang; Rui-Jin Liu; Yan-Song Liu; Hong-Liang Wang
Journal:  World J Gastroenterol       Date:  2017-06-28       Impact factor: 5.742

3.  SMASH standardised perioperative management of patients operated with acute abdominal surgery in a high-risk setting.

Authors:  Terje Jansson Timan; Ninni Sernert; Ove Karlsson; Mattias Prytz
Journal:  BMC Res Notes       Date:  2020-03-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.